Indaptus Therapeutics Q2 EPS $(0.39) Beats $(0.58) Estimate
Portfolio Pulse from Happy Mohamed
Indaptus Therapeutics reported Q2 losses of $(0.39) per share, beating the analyst consensus estimate of $(0.58) by 32.76 percent. This represents a 15.22 percent increase over losses from the same period last year.
August 14, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Indaptus Therapeutics' Q2 losses were less than expected, which could be seen as a positive sign by investors.
Indaptus Therapeutics reported lower than expected losses for Q2, which could be interpreted as a positive sign by investors. This could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100